Invasive Aspergillosis: Current Strategies for Diagnosis and Management

Jose Cadena, George Richard Thompson, Thomas F. Patterson

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Aspergillosis remains a significant cause of morbidity and mortality in the immunocompromised population. The spectrum of disease is broad, ranging from severe and rapidly fatal infection to noninvasive disease. The diversity of patients and risk factors complicates diagnostic and therapeutic decision-making. Invasive procedures are often precluded by host status; noninvasive diagnostic tests vary in their sensitivity and specificity. Advancements in understanding the pathophysiology of invasive aspergillosis and host genetics in differential risk have also occurred. Future work may assist in therapeutic decision-making and patient prognosis. Voriconazole remains the preferred agent for treatment. Additional alternatives have emerged.

Original languageEnglish (US)
Pages (from-to)125-142
Number of pages18
JournalInfectious Disease Clinics of North America
Volume30
Issue number1
DOIs
StatePublished - Mar 1 2016

Fingerprint

Aspergillosis
Decision Making
Routine Diagnostic Tests
Therapeutics
Morbidity
Sensitivity and Specificity
Mortality
Infection
Population

Keywords

  • Aspergilloma
  • Aspergillosis
  • Chronic cavitary aspergillosis
  • Invasive pulmonary aspergillosis
  • Resistance

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Invasive Aspergillosis : Current Strategies for Diagnosis and Management. / Cadena, Jose; Thompson, George Richard; Patterson, Thomas F.

In: Infectious Disease Clinics of North America, Vol. 30, No. 1, 01.03.2016, p. 125-142.

Research output: Contribution to journalReview article

@article{5d247f2045704da6b70a92ac4b471d9b,
title = "Invasive Aspergillosis: Current Strategies for Diagnosis and Management",
abstract = "Aspergillosis remains a significant cause of morbidity and mortality in the immunocompromised population. The spectrum of disease is broad, ranging from severe and rapidly fatal infection to noninvasive disease. The diversity of patients and risk factors complicates diagnostic and therapeutic decision-making. Invasive procedures are often precluded by host status; noninvasive diagnostic tests vary in their sensitivity and specificity. Advancements in understanding the pathophysiology of invasive aspergillosis and host genetics in differential risk have also occurred. Future work may assist in therapeutic decision-making and patient prognosis. Voriconazole remains the preferred agent for treatment. Additional alternatives have emerged.",
keywords = "Aspergilloma, Aspergillosis, Chronic cavitary aspergillosis, Invasive pulmonary aspergillosis, Resistance",
author = "Jose Cadena and Thompson, {George Richard} and Patterson, {Thomas F.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.idc.2015.10.015",
language = "English (US)",
volume = "30",
pages = "125--142",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Invasive Aspergillosis

T2 - Current Strategies for Diagnosis and Management

AU - Cadena, Jose

AU - Thompson, George Richard

AU - Patterson, Thomas F.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Aspergillosis remains a significant cause of morbidity and mortality in the immunocompromised population. The spectrum of disease is broad, ranging from severe and rapidly fatal infection to noninvasive disease. The diversity of patients and risk factors complicates diagnostic and therapeutic decision-making. Invasive procedures are often precluded by host status; noninvasive diagnostic tests vary in their sensitivity and specificity. Advancements in understanding the pathophysiology of invasive aspergillosis and host genetics in differential risk have also occurred. Future work may assist in therapeutic decision-making and patient prognosis. Voriconazole remains the preferred agent for treatment. Additional alternatives have emerged.

AB - Aspergillosis remains a significant cause of morbidity and mortality in the immunocompromised population. The spectrum of disease is broad, ranging from severe and rapidly fatal infection to noninvasive disease. The diversity of patients and risk factors complicates diagnostic and therapeutic decision-making. Invasive procedures are often precluded by host status; noninvasive diagnostic tests vary in their sensitivity and specificity. Advancements in understanding the pathophysiology of invasive aspergillosis and host genetics in differential risk have also occurred. Future work may assist in therapeutic decision-making and patient prognosis. Voriconazole remains the preferred agent for treatment. Additional alternatives have emerged.

KW - Aspergilloma

KW - Aspergillosis

KW - Chronic cavitary aspergillosis

KW - Invasive pulmonary aspergillosis

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=84958172769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958172769&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2015.10.015

DO - 10.1016/j.idc.2015.10.015

M3 - Review article

C2 - 26897064

AN - SCOPUS:84958172769

VL - 30

SP - 125

EP - 142

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 1

ER -